Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Total Therapy 3 for Newly Diagnosed Multiple Myeloma
NCT01055301Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2011
- Primary completion
- Jul 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, thalidomide, lenalidomide in multiple myeloma (MM), sponsored by SWOG Cancer Research Network. Planned start Jul 2011; status: withdrawn.
02
Drugs
bortezomibthalidomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01055301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01055301.